Skip to content
Chlorambucil
Leukeran (chlorambucil) is a small molecule pharmaceutical. Chlorambucil was first approved as Leukeran on 1982-01-01. It is used to treat b-cell chronic lymphocytic leukemia, breast neoplasms, choriocarcinoma, hodgkin disease, and non-hodgkin lymphoma amongst others in the USA.
Download report
Favorite
Searched
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
urogenital diseasesD000091642
cardiovascular diseasesD002318
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
endocrine system diseasesD004700
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Leukeran
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Chlorambucil
Tradename
Company
Number
Date
Products
LEUKERANWOODWARD SPECLN-010669 RX1982-01-01
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
leukeranNew Drug Application2023-05-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
b-cell chronic lymphocytic leukemiaD015451C91.1
breast neoplasmsEFO_0003869D001943C50
choriocarcinomaD002822C58
hodgkin diseaseD006689C81
non-hodgkin lymphomaD008228C85.9
ovarian neoplasmsEFO_0003893D010051C56
testicular neoplasmsD013736C62
thrombocytosisD013922D75.83
waldenstrom macroglobulinemiaD008258C88.0
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01A: Alkylating agents
L01AA: Nitrogen mustard analogues
L01AA02: Chlorambucil
HCPCS
Code
Description
S0172
Chlorambucil, oral, 2 mg
Clinical
Clinical Trials
51 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
B-cell chronic lymphocytic leukemiaD015451C91.158182132
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223C85.91528
LeukemiaD007938C9533
B-cell lymphoma marginal zoneD018442C88.4112
Membranous glomerulonephritisD015433EFO_0004254N03.211
Focal segmental glomerulosclerosisD005923EFO_000423611
NeoplasmsD009369C8011
Waldenstrom macroglobulinemiaD008258C88.011
Stomach neoplasmsD013274EFO_0003897C1611
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Mantle-cell lymphomaD020522C83.1112
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.011
Pancreatic ductal carcinomaD02144111
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-hodgkin lymphomaD008228C85.911
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCHLORAMBUCIL
INNchlorambucil
Description
Chlorambucil is a monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia. It has a role as an alkylating agent, a carcinogenic agent, an antineoplastic agent, an immunosuppressive agent and a drug allergen. It is a nitrogen mustard, an organochlorine compound, an aromatic amine, a tertiary amino compound and a monocarboxylic acid.
Classification
Small molecule
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1
Identifiers
PDB
CAS-ID305-03-3
RxCUI2346
ChEMBL IDCHEMBL515
ChEBI ID28830
PubChem CID2708
DrugBankDB00291
UNII ID18D0SL7309 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 8,317 documents
View more details
Safety
Black-box Warning
Black-box warning for: Leukeran
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
238 adverse events reported
View more details